AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35302197
Drug: Sodium bicarbonated
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonated Ringer's solution
Trial: 32488427
Drug: Trazodone ER
RxNorm normalized name: trazodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone ER formulation (300 mg)
Trial: 32488427
Drug: Originator Trittico
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator Trittico XR (300 mg)
Trial: 35921451
Drug: Prasinezumab 1500
RxNorm normalized name: Prasinezumab
DrugBank: Prasinezumab (DB14788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasinezumab 1500 mg
Trial: 35921451
Drug: Prasinezumab 4500
RxNorm normalized name: Prasinezumab
DrugBank: Prasinezumab (DB14788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasinezumab 4500 mg
Trial: 35921451
Drug: Infusion reactions
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion reactions
Trial: 32794259
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg aldafermin
Trial: 32794259
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg aldafermin
Trial: 32794259
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg aldafermin
Trial: 32794259
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg aldafermin
Trial: 34521108
Drug: Id-KLH vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Id-KLH vaccine
Trial: 32632489
Drug: WI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WI plus L-TAP
Trial: 35034023
Drug: Titration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration group
Trial: 33825070
Drug: PA +
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA + Charity (N=26; Fitbit, step goal, electronic weekly newsletter + charity donation if step goal achieved)
Trial: 33825070
Drug: PA (N=25;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA (N=25; Fitbit, step goal, electronic weekly newsletter)
Trial: 32545062
Drug: Iron tablets
RxNorm normalized name: Iron 65 MG Oral Tablet [LEADER IRON TABLETS]
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron tablets
Trial: 35316569
Drug: Thrombosis events
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thrombosis events (TE) during therapy for ALL
Trial: 33394100
Drug: Antiparkinsonian medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparkinsonian medication
Trial: 37384061
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic adjuvant chemotherapy (MAC) consisting of weekly methotrexate (15 mg/m2) and celecoxib (200 mg PO BD) for 18 months
Trial: 33509019
Drug: Breviscapine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breviscapine (120 mg daily for 14 days)
Trial: 34649982
Drug: High-dose CIMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CIMT
Trial: 34649982
Drug: Moderate-dose CIMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose CIMT
Trial: 34649982
Drug: Usual Customary
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Customary Treatment (UCT)
Trial: 32597565
Drug: NBD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBD regimen (sequential nephron blockade with diuretics)
Trial: 32597565
Drug: RASB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RASB regimen (sequential renin-angiotensin system blockade)
Trial: 33551347
Drug: ACLA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLA group (colloidal bismuth pectin 200 mg thrice a day, lansoprazole 30 mg twice a day, amoxicillin 1 g twice a day, antofloxacin 200 mg once a day)
Trial: 33551347
Drug: LCLA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCLA group (levofloxacin 500 mg once a day)
Trial: 34308678
Drug: Cold rub
RxNorm normalized name: Vaporizing Cold Rub
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold rub gel
Trial: 36084714
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after stent placement
Trial: 32176092
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine Shenqi Compound
Trial: 32176092
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment combined with Chinese medicine placebo
Trial: 33588801
Drug: Prophylactic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic metformin 500 mg twice daily for 72 hours
Trial: 38918695
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Trial: 34532888
Drug: Itraconazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (all doses)
Trial: 36468403
Drug: Active BP
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active BP lowering treatment (combination perindopril±indapamide)
Trial: 33476415
Drug: Oral sulfate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfate solution same-day dose (n=200)
Trial: 33476415
Drug: Oral sulfate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfate solution split-dose (n=202)
Trial: 38174567
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and placebo
Trial: 36484364
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (3 times per week during irradiation, diode laser: 660 nm, 75 mW, 1.5 cm2, 50 mW/cm2, 60 seconds exposure, 3 J/cm2, 20-30 spots per session)
Trial: 36484364
Drug: Sham low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham low-level laser therapy (identical delivery method to low-level laser therapy)
Trial: 32784153
Drug: Loaded Dix-Hallpike
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loaded Dix-Hallpike (L-DH)
Trial: 36317751
Drug: SHR4640 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 (10 mg) under fed conditions
Trial: 36317751
Drug: SHR4640 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 (10 mg) under fasted conditions
Trial: 36317751
Drug: SHR4640 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 (10 mg)
Trial: 32853584
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg orally daily from 21 days preoperatively to postoperative day 7
Trial: 32853584
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days before surgery
Trial: 32853584
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (per-protocol analysis)
Trial: 35768027
Drug: Treatment received
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment received aligned with recommendations
Trial: 35768027
Drug: Discordant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discordant treatment recommendations
Trial: 35768027
Drug: Urologists' and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urologists' and radiation oncologists' treatment recommendations
Trial: 32464351
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of 5-Hydroxytryptophan (5-HTP) daily
Trial: 36125279
Drug: Lasmiditan 50
RxNorm normalized name: lasmiditan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan 50 mg
Trial: 34229295
Drug: Epidemiological research,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidemiological research, case studies, single-arm treatment studies, randomized controlled treatment trials, and objective sleep study data
Trial: 33749219
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed freehand by experienced clinicians
Trial: 33017456
Drug: 90 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g/day low-carbohydrate diet (LCD)
Trial: 32172599
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral Therapy (ART) adherence strategies
Trial: 32195538
Drug: Daily isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily isocaloric meal with standardized amount of avocado (males: 175 g; females: 140 g) for 12 weeks
Trial: 32195538
Drug: Daily isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily isocaloric meal with standardized amount of avocado
Trial: 35602971
Drug: BCAA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (30 g, b.i.d. for 21 days)
Trial: 35602971
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose (placebo, 30 g, b.i.d. for 21 days)
Trial: 35602971
Drug: Rice protein
RxNorm normalized name: rice protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice protein (placebo, 30 g, b.i.d. for 21 days)
Trial: 34391828
Drug: Statins treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins treatment
Trial: 34391828
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy combined with statins
Trial: 33857412
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 18 doses
Trial: 33857412
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 18 doses in PD-L1-positive patients
Trial: 36453188
Drug: Povidone-iodine rectal
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine rectal cleansing
Trial: 36453188
Drug: No povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No povidone-iodine rectal cleansing (Control)
Trial: 35287025
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) administered three times (median, range 1–5 times), with an interval of 9.5 months (mean [SD]) under B cell monitoring.
Trial: 35287025
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) monotherapy, 28 (90%) of 31 patients treated with RTX.
Trial: 35287025
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) administration under B cell monitoring.
Trial: 32156544
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion)
Trial: 33819508
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT)
Trial: 35570699
Drug: Oral SDX
RxNorm normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SDX (120 mg)
Trial: 35570699
Drug: Oral SDX
RxNorm normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SDX (240 mg)
Trial: 35570699
Drug: IN SDX
RxNorm normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN SDX (80 mg)
Trial: 35570699
Drug: IV SDX
RxNorm normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV SDX (30 mg)
Trial: 35570699
Drug: d-MPH (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-MPH (80 mg)
Trial: 35570699
Drug: d-MPH (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-MPH (40 mg)
Trial: 35570699
Drug: d-MPH (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-MPH (15 mg)
Trial: 33025052
Drug: Episealer implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episealer implant
Trial: 36316692
Drug: Low pre-RRT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l)
Trial: 36316692
Drug: Low pre-RRT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at day 3 of RRT
Trial: 36409018
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg, doubled if no response at 2 weeks)
Trial: 32996010
Drug: D-Mg2+ at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Mg2+ at 0.75 mmol/L
Trial: 33066944
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin therapy in combination with dynamic electric neurostimulation and basic therapy
Trial: 33066944
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin therapy and basic therapy
Trial: 33066944
Drug: Dynamic electric
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic electric neurostimulation and basic therapy
Trial: 37942277
Drug: tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 5 mg twice daily
Trial: 36329128
Drug: Combined pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pressure garment and topical silicone gel therapy
Trial: 36461619
Drug: Facemask pre-oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask pre-oxygenation (100% oxygen, 6 L/min)
Trial: 34506606
Drug: Oscillating protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating protein diet (OP, 125 and 173 g/kg CP diets oscillated at 2‐d intervals)
Trial: 34506606
Drug: Static protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static protein diet (SP, 149 g/kg CP)
Trial: 32791692
Drug: Intranasal phototherapy
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal phototherapy for 20 minutes, 3 times a week for 4 weeks
Trial: 32711440
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (400 mg/kg body weight per day)
Trial: 33748833
Drug: High-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose influenza vaccine
Trial: 33748833
Drug: Standard-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose influenza vaccine
Trial: 34544820
Drug: Ofatumumab (1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (1.50 mg/1.73 m2)
Trial: 33121452
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose clopidogrel (150 mg per day) + aspirin (100 mg per day) over 21 days
Trial: 33121452
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose clopidogrel (75 mg per day) + aspirin (100 mg per day) over 21 days
Trial: 33121452
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose clopidogrel + aspirin
Trial: 33121452
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose clopidogrel + aspirin
Trial: 36223114
Drug: iTBS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTBS plus D‐cycloserine (100 mg)
Trial: 32441467
Drug: Chlortetracycline hydrochloride
RxNorm normalized name: Chlortetracycline Hydrochloride
DrugBank: Chlortetracycline (DB09093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlortetracycline hydrochloride ointment (Control)
Trial: 34854987
Drug: RCT (Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT (Root Canal Therapy)
Trial: 36264378
Drug: Pembrolizumab-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab-chemotherapy
Trial: 35381576
Drug: Cetuximab-chemotherapy
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab-chemotherapy
Trial: 32717127
Drug: Structured teaching
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured teaching module including intensive prophylactic measures administered by a trained oncology nurse
Trial: 32717127
Drug: Standard information
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard information on HFS care administered by treating clinician (control)
Trial: 34935407
Drug: Dabigatran vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran vs Warfarin
Trial: 34953525
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abiraterone acetate 1000 mg daily + prednisolone 5 mg daily)
Trial: 34953525
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abiraterone acetate + prednisolone + enzalutamide 160 mg daily)
Trial: 34953525
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abiraterone acetate + prednisolone)
Trial: 34478577
Drug: Low-dose anfibatide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anfibatide (2 IU/60 kg)
Trial: 34478577
Drug: Moderate-dose anfibatide
RxNorm normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose anfibatide (3 IU/60 kg)
Trial: 34478577
Drug: High-dose anfibatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anfibatide (5 IU/60 kg)
Trial: 33407774
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (40 mg)
Trial: 34292203
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg per day
Trial: 33652129
Drug: Blinded acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded acetaminophen
Trial: 33652129
Drug: Blinded ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Blinded ibuprofen
Trial: 33652129
Drug: Control (OTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (OTC medications)
Trial: 34877813
Drug: Edoxaban 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 75 mg
Trial: 32207274
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir administered according to the 3-0-3 titration algorithm (G3)
Trial: 32207274
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir administered according to the 2-4-6-8 titration algorithm (G2)
Trial: 33301990
Drug: MOCHA Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOCHA Standard intervention (10-week program including small group discussions, health topic classes, and 60-min aerobic exercise twice a week)
Trial: 32147440
Drug: Aggressive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive local treatment (surgery) for oligometastatic disease in gastric cancer
Trial: 32717341
Drug: Implant placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant placement in at least 1 eye